NAD Therapy Evidence Boundary

Definition

NAD therapy evidence boundary separates biochemical plausibility and reported patient responses to intravenous or subcutaneous NAD from established clinical efficacy for fatigue, mood, cognition, infection, addiction, sleep, or longevity.

Current Synthesis

The source presents NAD as a mitochondrial and cellular-energy intervention delivered intravenously, subcutaneously, or indirectly through oral precursors such as NMN or NR. Koniver and Huberman describe striking personal and patient experiences involving COVID symptoms, chronic fatigue, depression, creativity, language, energy, sleep efficiency, and mental clarity, along with clinic-specific loading and maintenance patterns.

The current judgment remains cautious because the episode offers anecdotes and mechanistic explanation rather than controlled outcome evidence. Route, dose, infusion speed, cost, tolerability, indication, and follow-up all change the intervention, and rapid improvement after treatment does not by itself establish causation or general benefit.

Key Claims

• NAD’s role in cellular metabolism makes it a plausible intervention target but does not establish a clinical indication.
• Intravenous, subcutaneous, NMN, and NR approaches differ in delivery, cost, tolerability, and evidentiary status.
• Reported changes in fatigue, mood, cognition, sleep, or infection are hypothesis-generating clinical observations.
• Loading and maintenance schedules described by one clinic are not validated general protocols.
• Adverse effects, concurrent care, natural recovery, selection effects, and placebo or expectation effects remain relevant alternative explanations.

Evidence

• Routes and protocols - Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver compares intravenous NAD, subcutaneous NAD, NMN, and NR and describes one clinic’s dosing patterns.
• Reported outcomes - Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver records personal and patient anecdotes involving COVID, Epstein-Barr-related fatigue, depression, creativity, energy, sleep, language, and mental clarity.
• Limitations - Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver does not provide controlled comparisons, effect sizes, systematic adverse-event data, or long-term outcomes for these uses.

Counterevidence & Qualifications

The episode’s temporal associations do not prove that NAD caused the reported improvements, and a negative COVID test after an infusion does not establish antiviral efficacy. This page does not establish that intravenous NAD is superior to subcutaneous NAD or oral precursors, nor that any route treats addiction, infection, fatigue, depression, cognitive symptoms, sleep problems, or aging.

What Changed

• Created the concept to preserve the gap between prominent clinical anecdotes and established NAD treatment evidence.

Related Concepts

• Mitochondrial Lifestyle Pillars - broader framework connecting mitochondrial function to sleep, nutrition, exercise, stress, and other inputs.
• Mitochondrial Energy Allocation - cellular-energy context that should remain distinct from intervention efficacy.
• Medical Risk Management - supervision, contraindication, adverse-effect, and follow-up boundary.
• Self-Experimentation - personal testing mode that can generate observations without controlled causal evidence.
• Peptide Evidence Hierarchy - analogous evidence-sorting discipline for emerging biological interventions.